BioCentury
ARTICLE | Clinical News

Brilacidin: Phase II started

June 27, 2016 7:00 AM UTC

Cellceutix began an observer-blind Phase II trial to evaluate 3 dose levels of once-daily brilacidin given via retention enema for 6 weeks in 18 patients. ...